Publications by authors named "Caitlyn McCarthy"

Claim this Profile
V
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study.
Jean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, Cissy Kityo, Michael D Hughes

Lancet HIV· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites.
Cissy Kityo, Caitlyn McCarthy, Serena P Koenig, Michael D Hughes, Carole L Wallis

Open Forum Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluid.
Sean N Avedissian, Ying Mu, Caitlyn McCarthy, Ronald J Bosch, Serena Spudich

Pharmacotherapy· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries.
N Sarita Shah, Cissy Kityo, Michael D Hughes, Caitlyn McCarthy, Carole L Wallis

Clin Infect Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
Prasanna Jagannathan, Kara W Chew, Mark J Giganti, Michael D Hughes, Carlee Moser, Caitlyn McCarthy

EClinicalMedicine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Anchalee Avihingsanon, Michael D Hughes, Robert Salata, Catherine Godfrey, Caitlyn McCarthy

J Int AIDS Soc· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis